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Abstract: While the doubling of life expectancy in developed countries during the 20th 
century can be attributed mostly to decreases in child mortality, the trillions of dollars 
spent on biomedical research by governments, foundations and corporations over the past 
sixty years are also yielding longevity dividends in both working and retired population. 
Biomedical progress will likely increase the healthy productive lifespan and the number of 
years of government support in the old age. In this paper we introduce several new 
parameters that can be applied to established models of economic growth: the biomedical 
progress rate, the rate of clinical adoption and the rate of change in retirement age.  
The biomedical progress rate is comprised of the rejuvenation rate (extending the 
productive lifespan) and the non-rejuvenating rate (extending the lifespan beyond the age 
at which the net contribution to the economy becomes negative). While staying within the 
neoclassical economics framework and extending the overlapping generations (OLG) 
growth model and assumptions from the life cycle theory of saving behavior, we provide 
an example of the relations between these new parameters in the context of demographics, 
labor, households and the firm. 
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1. Introduction 
Increases in productivity, technological progress and population growth have been identified as the 
main drivers of economic growth [1‒3]. The endogenous growth theory expands on the underlying 
factors that affect technological advancement by focusing on human capital [4,5]. The unified 
economic theories further build on these ideas, incorporating elements of natural selection into growth 
models to explain an economy’s transition from stagnation to growth [6]. 
However, all of these models may be further extended to account for the rate and nature of 
technological advances, as well as for the lifespan, average years in the workforce, and the retirement 
age of the population. The past fifty years have seen more advances in science and technology than the 
rest of human history [7]. Concurrently, the world population has more than doubled, growing from 3 
billion in 1960 to 7 billion in 2012 [8]. Life expectancies, meanwhile, have increased steadily across 
all segments of the population over the last twenty years [9]; Figure 1A–C; these figures were 
generated using R software using the data from National Center for Health Statistics, Health, United 
States, 2011 and 2012) [10,11]. These trends significantly increase the number of older people in the 
population and the length of time these people remain dependent on social security and healthcare 
systems after retirement. Recent studies have demonstrated that generational accounting may affect 
economic growth and must be included when evaluating the state of an economy [12]. Recent studies 
introduced the economic models for the notion of modifiable life spans and started raising the 
awareness of life spans rising beyond the “natural” improvements of life expectancy [13]. However,  
the effects of aging on economic growth remains a controversial topic in macroeconomics with some 
studies suggesting a positive relationship between longevity and growth due to the prevalence of the 
effects of capital accumulation [14] or shifts in labor force participation [15]. Studies from Japan 
proposed positive relationship between population aging and economic growth in a general 
equilibrium model of life cycle savings combined with endogenous growth and even suggested that 
postponing the retirement age will have a negative effect on economic growth [16].  
Other theoretical models suggest the negative effect of aging on economic growth due to the 
increase in the dependence rate leading to reallocation of labor from non-health to health production [17]. 
Other studies using empirical evidence demonstrate the ambiguous effects of population aging on 
economic growth and suggest that in the economy, where the availability of capital is endogenously 
determined by domestic savings, the capital accumulation effect prevails and population aging leads to 
the economic growth [18]. 
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Figure 1. Life expectancy by age in the United States in the first decade of the twenty  
first century. (A) Life expectancy at birth. (B) Life expectancy at age 65.  
(C) Life expectancy at age 75. Data is provided by National Center for Health Statistics. 
Health, United States, 2012. 
 
Many technological advances occur at an exponential rate; for instance, Moore’s law, which states 
that computing power doubles every two years, has held for almost half a century [7,19]. However, in 
many areas of biomedicine, a field in which new discoveries can result in significant increases in the 
human lifespan, progress is much slower [20]. Innovations in information technology enter mainstream 
use rapidly, sometimes in a matter of months. Discoveries in the biomedical sciences, however, require 
thorough testing in laboratory animals and lengthy human trials, which delay the mass adoption of 
these innovations by years or even decades. As a result, life expectancies tend to grow slowly, 
increasing by just 2–3 years every decade. At this pace, it would take close to three hundred years for 
human life expectancy to double—a far cry from the rate of progress achieved by other disciplines. 
Thus, the demographic effects of biomedical discoveries made after 1990, such as increases in 
lifespan and ability to perform useful work, will not be noticeable until at least 2030. Some promising 
21st century advances that have the potential to increase life expectancy, like induced pluripotent stem 
cells and in-vitro organs made from endogenous patient cells, will not reach clinical practice for at 
least another decade [21,22]. The impact of recent advances in the biomedical sciences is also 
obscured by the detrimental effects of unhealthy lifestyle changes, such as easy and affordable access 
to high-calorie foods and a lack of physical activity, which apply negative pressure to the life 
expectancy curve. 
1.1. Recent Acceleration of Biomedical Progress 
In recent years, many areas of science and technology have experienced exponential growth in the 
number of scientists doing research in the field, funding and scientific publications. While many of the 
discoveries that have most dramatically transformed modern society have been concentrated in the 
field of information technology (for instance, cell phones, computers and the Internet), biomedical 
advances have accelerated at a similar pace. There have been more discoveries made in the biomedical 
field since 1960 than during the entirety of human history prior to 1960 [23]. The general paradigm of 
performing biomedical research and applying it to clinical practice involves seven major steps: 
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1. Conception of the idea 
2. Describing the idea and applying for research grants 
3. Performing experiments  
4. Publishing the experimental results 
5. Preclinical proof of efficacy and safety 
6. Clinical trials 
7. Mainstream clinical adoption  
Scientific publications are an excellent indicator of biomedical progress. Medline, the centralized 
resource developed by the US National Library of Medicine, is used for indexing and tracking 
scientific publications. From 1993 to 2011, the number of scientific publications indexed in Medline 
increased from just over 400 thousand to just under one million papers per year [24]. In recent years, 
this number has grown even more dramatically as emerging countries increase their contributions to 
international science.  
Scientific grants, which measure future advances in biomedicine, may be an even better indicator of 
progress. Years or even decades may pass between the awarding of a grant and the publication of 
experimental results, but most funding institutions publish grant information after the grant is awarded. 
The resource developed by our team, the International Aging Research Portfolio (IARP), tracks the 
grant data available from major funding organizations in the US, Europe, Canada and Australia [25]. 
Annual science funding in the form of grants tracked by the IARP increased from just over $5 billion 
per year in 1993 to over $45 billion in 2011. This figure may be much more significant if other funding 
sources are accounted for. Similarly, private sector spending on R&D increased from over $35 billion 
in 1996 to over $95 billion in 2009 [26], with the top 15 pharmaceutical companies accounting for 
over $75 billion of the total. We expect this trend to continue in the coming years, fueling the number 
of publications, clinical trials and clinical procedures with the potential to extend life expectancy. 
1.2. Longevity and Healthy Productive Lifespan 
1.2.1. Life Extension vs. Rejuvenation Rate 
For the purposes of this model we assume that biomedical progress has a positive effect on life 
expectancy. Further, biomedical progress may be separated into two rates:  
1. Rejuvenation rate—the sum of all developments extending a person’s ability to perform useful 
work and restoring function lost due to aging, disease or injury.  
2. Non-rejuvenating biomedical progress rate—the sum of all developments that extend the 
lifespan, but do not extend the person’s ability to perform useful work or restore lost function.  
Here we separate the rate of biomedical advances into two categories: the rejuvenation rate and 
non-rejuvenating biomedical progress rate. The concept is illustrated in Figure 2. Examples of 
biomedical developments extending the maximum productive age include preventative cancer 
vaccines, arthritis and diabetes treatments. Examples of non-rejuvenating developments include  
late-stage cancer, multiple sclerosis and other medications marginally extending patient’s life near end 
of life.  
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Figure 2. Rejuvenation Rate vs. Non-rejuvenating Biomedical Progress Rate. The figure 
depicts the hypothetical person’s lifespan, where the rate of biomedical and technology 
progress is comprised of the Rejuvenation Rate (RR) extending Maximum Productive Age 
and Non-rejuvenating Biomedical Progress Rate (NBPR) delaying the Age of Death, while 
not restoring the ability to do useful work.  
 
The non-rejuvenating treatments are usually partially covered by insurance, but are expensive and 
in many cases exceed the family’s ability to afford the treatments. In 2007 in the US 61.2% of personal 
bankruptcies were healthcare-related [27]. In OECD countries the majority of healthcare expenditures 
are spent for the care of the terminally ill and costs increase with the age of the patients [28]. 
Population aging results in a rapid increase in healthcare expenditures [29,30]. A significant part of 
these expenses falls on the government thereby increasing public spending and fiscal deficits. This 
problem starts at the root source of the biomedical pipeline, where governments and companies focus 
on taking the treatments that extend life in terminally-ill patients because it is easier to conduct these 
studies and expedite the propagation of these treatments into clinical practice in the tight regulatory 
environment. Proving the efficacy of the preventative treatments may take many decades and the 
compensation mechanisms for these treatments are not clear. Using pattern analysis algorithms it may 
be possible to analyze the current research clinical trials pipelines and re-focus the research activities 
to accelerate the rejuvenation rate.  
2. Model 
Our model is based on the OG model and on the life-cycle theory of saving behavior [31].  
The economy consists of two types of agents: households and the firm. We incorporate three new 
features into the model:  
(i) Rejuvenation rate (RR)—the rate at which the functions required to perform useful work that 
were lost to aging or disease are restored; 
(ii) Non-rejuvenating rate of biotechnical progress (NRPR)—the rate of biotechnical progress 
that increases lifespan, but does not return lost functions; 
(iii) Biomedical science and technology progress rate (BMTPR)—the rate at which progress in 
science and technology and the application of these technologies to clinical practice extends 
the lifespan of the population. It is equal to RR + NRPR. 
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Additional parameters introduced into the OLG model are summarized in Table 1 and the list of 
basic functions is summarized in Table 2. 
Table 1. Basic Parameters. 
Designation Description Comment 
A Age  
t Time  
R 
Rejuvenation 
Partial or complete restoration of the ability to perform useful work lost due to 




The rate at which advances in technology and the natural, social and 
behavioral sciences and the mainstream adoption of these advances lead to the 
partial or compete restoration of the ability to perform useful work lost to 
illness, injury or aging. Example: advances in arthritis treatment and 
prevention, procedures that restore vision, software products assisting with 




The age set by the government at which the individual is entitled to receive full 
social security and healthcare benefits 
 
NRPR 
Non-rejuvenating progress rate 
Advances in science and technology and the mainstream adoption of these 
advances that extend lifespan but does not restore the ability to perform useful 
work. Example: drugs and therapies that increase survival of terminally ill 
patients by several months, but do not restore healthy function and the ability 
to perform useful work.  
The rate of biotechnical 
progress that increases 
lifespan, but doesn’t 
return lost functions. 
BMTPR 
Biomedical science and technology progress rate 
The rate at which progress in science and technology and the application of 
these technologies to medical practice extends the lifespan of the population. It 
is equal to RR+NRPR 
 
Aaver The average lifespan   
MPA 
Maximum productive age 
The age at which the ability to do useful work is diminished. The age may be 
increased through rejuvenation (R). 
 
Amax Maximum lifespan  
Table 2. Basic functions. 
Designation Description Comment 
N (A,t, BMTPR) The number of people of age A in period t  
Pr (A,t,RR, BMTPR) The productivity of labor  
Wr (A,t, BMTPR ) 
The ratio of the working population of age 
(A) to the total population of age (A) 
 
В (RR) Biological retirement age  
The age at which a person can no longer work due 
to biological reasons, i.e., illness.  
Ls(RR) 
The percentage of people that will retire at 
age S 
 
Mr (A,BMTPR) Mortality rate 
0 < Mr < 1 
The probability of dying at age A 
Br(t) Birth rate 
The ratio of the number of newborns in period t to 
the total number of people in the population 
AdRate(t) 
The mainstream clinical adoption rate of 
biomedical discoveries 
The rate of adoption of biomedical discoveries by 
hospitals and doctors.  
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Households are assumed to be rational, production technology is given by a standard Cobb-Douglas 
function, and the one-good economy is assumed to be closed. Bequest motives are not included [31]. 
2.1. Demographics 
The economy consists of people, aged from 0 to Amax, denoted by i = 0; 1; 2; …; Amax. In each new 
period t, a new generation aged 0 is born into the economy, while each of the existing generations 
shifts forward by one. The oldest generation, i = Amax, which we assume to be the maximum age,  
dies out.  
We assume that each age is characterized by a mortality rate—the percentage of people of that age 
that will die. The mortality rate is described by the function: 
 
(1)
where Aaver—average lifespan; α, β and γ—parameters for normalizing the mortality rate, N
A—number 
of people at the age A.  
This distribution takes into consideration the correlation between mortality rate and age, based  
on the statistical data provided by mortality.org (See Figure 3). It also allows people to achieve 
maximum age. 
Figure 3. Mortality rate in the United States in 2010. The X-axis represents age and the Y-axis 
represents the mortality rate in percent. The mortality rate is calculated as the ratio of the 
number of deaths among people of a certain age to the total number of people of a certain age.  
 
Because it can take many years for medical professionals to adopt a life-prolonging biomedical 
discovery, the mortality rate formula includes the mainstream clinical adoption rate of these 
discoveries (AdRate):  
 
(2) 
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According to the above formula, the adoption rate of a biomedical discovery in year t is the sum of 
adoption rates from year 1, when the discovery is made, to year t. The adoption rate for a certain year 
can be characterized as the percentage of medical institutions in the country that start using the 
discovery during that year. For instance, if 2% of all medical institutions begin using a new biomedical 
procedure in the first year after its discovery, and a further 10% begin using it in the subsequent year, 
the AdRate for year 2 would be 12%. Of course, AdRate is a function and could change from period to 
period. Also, AdRate cannot, by definition, exceed 1.  
Combining all of these these parameters, the number of people living in the economy at the 
beginning of period t + 1 is calculated as: 
 
(3)
2.2. Employment and Labor 
(1) We assume that the percentage of people of age A in the labor force is described by the function:  
 
(4)
where S the age set by the government at which the individual is entitled to receive full social security 
and healthcare benefits B which denotesthe age at which a person can no longer work due to biological 
reasons, i.e., illness, χ—proportion of the population that enters the labor force between 16 and 25 
years of age. This parameter is introduced since people do not enter the labor force all at once; rather, 
labor force participation increases steadily between ages 16 and 25 (See Figure 4). 
Figure 4. Employment rate by age group in the United States in 2012. The X-axis 
represents age and the Y-axis represents the employment rate, calculated as the ratio of 
employed population in the labor force to total population in the labor force. 
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δ1—the proportion of the population that will exit the labor force after the retirement age set by the 
government (S) and before the biological retirement age (B). This parameter is introduced since people 
do not exit the labor force at the same time. This paradigm may change as a result of shifts in the 
retirement culture—for instance, more people may choose to work until their biological capacity is 
exhausted. Moreover, it has been demonstrated that a notable proportion of older workers can perform 
tasks as competently as their younger counterparts [32,33]. 
δ1 << 1 (5)
δ2—the proportion of the population that will exit the labor force after the biological retirement age. 
This parameter is introduced since some people will continue working throughout their entire lives, 
even after exhausting most of their biological capacity for work. We assume that after reaching the 
biological retirement age, people exit the labor force faster than they do following the retirement age 
set by the government. 
δ2 > δ1 (6)
This distribution takes into account that people under age 16 are not working. 
S—the retirement age set by the government. At this age, a person can either decide to retire or 
continue working. Denote by P the percentage of people who choose not to retire upon reaching 
retirement age. 
B—the biological retirement age. At the biological retirement age and beyond, a person’s capacity 
to perform work effectively diminishes as a result of health issues.  
(2) We assume that the productivity of workers is not constant and depends on age, and is described 
by a Gaussian distribution. This model is based on the work of Lee and Yaari [34,35] and takes into 
account the finding that older workers can perform tasks as effectively as their younger counterparts:  
 
(7)
where φ = const—the parameter that takes into account the correlation between RR and Pr. 




Until retirement, households supply labor to the firm and earn wage (w) income according to their 
age-specific labor efficiency. 
Although studies modeling consumer behavior in light of uncertain lifetime exist [36], here we 
assumed only the representative households to estimate the lifetime utility. Households aged  
j > S start to withdraw from the labor force, and receive public pension benefits from the social 
security system. Households own capital and rent it to firms throughout their lives. They consume the 
rest of their income [34].  
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There is a representative firm producing final goods with the Cobb-Douglas production technology. 
In perfectly competitive spot-markets, the firm rents capital and hires labor from households so as to 
maximize its profit: 
 (11)
where Kt is aggregate capital stock, Lt is aggregate labor input, and Rt is the rental rate of private 
capital. At denotes the total factor productivity (hereafter TFP) in period t, and we assume that the TFP 
grows at the rate of gt in every period. 
2.5. Competitive Equilibrium 
A competitive equilibrium consists of:  
Households maximizing their lifetime utility:  
 
(12)
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Also we assume all markets clear, i.e., for all t, we have Lt = 1, bt = 0, and c1,t + c2,t + kt + 1 = F(kt, 1), 
where c1,t be worker t’s consumption when young, and let c2,t+1 be his consumption when old, kt is the 
t’s capital and F(kt, 1)—neoclassical production function [37]. 
2.6. Sensitivity Analysis to BMTPR 
BMTPR will have a positive effect on lifespan, productivity and biological retirement age, but its 
effect on the percentage of the population in the labor force depends on the RR/BMTPR ratio.  
When RR increases, the mortality rate will peak at a later age, decreasing Mr and increasing  
the lifespan (Figure 5): 
 
(15)
Figure 5. Mortality and rejuvenation rates. Mortality rate at age A is the percentage of 
people of age A that will die at age A. Rejuvenation rate is the rate at which advances  
in science and technology and the application of these advances to clinical practice lead to 
the partial or complete restoration of the ability to perform useful work lost to illness, 
injury or aging. 
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BMTPR will increase the biological age of retirement. The relationship between these two factors is 
likely to be linear.  
B = 60p·(1 + AdRate·BMTRP), where p is a parameter that takes into account the correlation 
between RR and B.  
By improving the quality of life, BMPTR will increase the time people spend in the labor force 
(Figure 6). Thus, the number of people who do not retire at age S will increase. Ls = Ls
0(1–RR)·p2, 
where p2 is a parameter that takes into account the correlation between RR and Ls. 
Statistics show that increases in a country’s average life expectancy are correlated with decreases in 
the birth rate, so we can conclude that an increase in RR will lead to decrease in birth rate. 
Figure 6. Effects of the rejuvenation rate on labor participation. Employment rate without 
BMTPR (BMTPR = 0) is represented by the black curve, with BMTPR (BMTPR ≠ 0) and 
RR/BMTPR << 1/2 is represented by red curve, with BMTPR (BMTPR ≠ 0) and 
RR/BMTPR >> 1/2 is represented by the green curve. The X-axis represents age.  
 
Workers’ productivity depends on their age (Figure 7); for instance, the productivity of teenagers is 
lower than the productivity of people in their thirties. Productivity also depends on the rejuvenation 
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Figure 7. Productivity and rejuvenation rate. The X-axis represents age and the Y-axis 
represents productivity. The black curve illustrates the relative productivity with age 
without rejuvenation rate. The red curve illustrates the relative productivity with age with 
rejuvenation rate. 
 
2.7. The Difference between the Effects of RR and BMTPR on the Economy 
It is worthwhile to note the difference between the effects of RR and NBPR. In particular,  
the rejuvenation rate increases the number of people who are able to work, while the non-rejuvenating 
progress rate increases the number of people who are unable to work. Thus, the effect of BMTPR on 
an economy depends on the RR/BMTPR ratio. For example, a RR/BMTPR ratio of less than 1 would 
result in a shortage of workers and a consequent decrease in economic growth. 
Most medical advances today extend the lifespan of sick people in the last months or years of their 
life without enabling them to make productive contributions to the economy. In the developed 
countries the majority of the lifetime healthcare costs are attributed to the last years of a patient’s life 
and the cost of healthcare is rapidly increasing with age in late life [37,38]. For example, new cancer 
drugs may extend cancer patients’ lives by several months compared to standard methods of care, but 
are significantly more expensive. The approval and clinical introduction of drugs like Dendreon’s 
Provenge vaccine have already triggered broad public cost/benefit debates [39]. Note that while a person 
remains unable to work, he or she does not contribute to GDP. Moreover, the cost of maintaining his 
or her life reduces GDP, even as the overall mortality of population declines:  
 
(18)
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This leads us to the conclusion that it is the RR/BMTPR ratio that affects the economy, rather than 
the RR or BMTPR in particular. Thus, biotechnical progress will lead to economic growth only if 
 
(19)
because if mortality decreases faster than the ability to work and the retirement age increase, the 
economy must maintain more pensioners. In contrast, by increasing the period of active life, we give a 
person the opportunity to work longer; as a result, fewer people reaching the government retirement 
age S will retire, and the rate of withdrawal from the labor force (α) is also reduced. 
To sum up the effects of the RR/BMTPR ratio on the economy, we analyze its influence on labor, 
which will lead to direct influence on GDP: 
 
(20)
If the RR/BMTPR ratio increases, such components of labor as PrA,RR, Wr
A,AdRate,BMTRP, (1−Mr
A)  
will increase, but N0
A(t) will decrease.  




The problem of unemployment will not occur if  
 
(22)
This implies that birth rate must decrease quicker than the number of people who are able to work 
increases. Statistics show that the speed of birth rate reduction accompanying increases in lifespan is 
very quick, which suggests that the economy would not face increasing unemployment in this scenario. 
As long as GDP in our model is strictly increasing with increase of labor, GDP will increase with 
RR/BMTPR ratio. 
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3. Conclusions 
In this paper, we have introduced several novel parameters that may be incorporated into the most 
commonly accepted theories of economic growth in addition to frequently cited factors like population 
growth, technology, behavior, capital flows, and distribution of capital. These parameters are a very 
recent phenomenon and can only be traced back for the past two decades. We propose a model that 
takes into account progress in the biomedical sciences, which in turn affects the size, growth and 
productivity of the population. In the model, the rate of biomedical progress is the sum of the 
rejuvenation rate, the rate at which the functions required to perform useful work that were lost to 
aging or disease are restored, and non-rejuvenating rate, which increases lifespan, but does not restore 
lost functions.  
We hypothesize that, over the past two decades, economic growth in the developed countries has 
been partially defined by the ratio of the rejuvenation rate to the overall biomedical progress rate and 
the retirement age. The biomedical progress rate extends the lifespan and decreases the mortality rates 
of the population, while the rejuvenation rate allows for the increased productivity of older workers 
and increases in the retirement age.  
We propose that the increase in the ratio of the rejuvenation rate to the overall biomedical progress 
rate will result in economic growth. This hypothesis is supported by recent studies showing that the 
acceleration of aging research focused on increasing longevity and postponing age-related diseases and 
not the treatment of age-related diseases [40]. Another source of economic growth may come from 
accelerating the rate of clinical adoption by reducing the time it takes for a biomedical discovery to 
reach the patient. 
The effects of population aging on economic growth remains a controversial topic in 
macroeconomics with conflicting schools of thought. While there are many models and simulations 
that account for population aging [41–43], the new parameters introduced in this paper may help 
enrich the models demonstrating both positive and negative effects of aging on the economy and help 
model scenarios that go beyond extending historic trends in longevity. 
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